Dr. Jang on current state of immunotherapy in advanced GU cancers

Acceptance of the IND application would initiate a first-in-human phase 1 dose expansion and escalation trial of CTIM-76 in patients with testicular and gynecologic cancers.

“When you compound the patient delay and…the physician delay, then you really get a delay in diagnosis,” says Curtis A. Pettaway, MD.

Preliminary data showed that the treatment was well-tolerated, and a maximum tolerated dose had not yet been reached.

“Because so many disease processes that we deal with are related to tobacco use and smoking specifically… I think this is absolutely our domain,” says Richard S. Matulewicz, MD, of tobacco cessation counseling and treatment.

Overall, 39.1% of patients with malignant ureteral obstruction were referred to palliative care over the study period.

The positioning system would allow patients with cancer to undergo radiation therapy in an upright, seated position.